Released Apr 25, 2023, before the open
10-Q filed Apr 26, 2023, 26 days after period end · 0001171843-23-002581
Q1 2023 · 10-Q
Revenue$29.98M$29.98M +4.2% vs Q1 2022+5.4% vs Q4 2022
Net Income$622.00K$622.00K N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted$0.01$0.01 N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$18,346,000+13.4%
Operating Income$1,749,000N/M
Operating Cash Flow$1,812,000N/M
Free Cash Flowderived$1,588,000N/M
Margins · derived
Gross margin61.2%+5.0 pt vs Q1 2022
Operating margin5.8%+29.2 pt vs Q1 2022
Net margin2.1%+26.0 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $29.98M | $28.78M | $26.99M | $23.77M |
| Net Income | $622.00K | -$6.88M | -$669.00K | -$4.52M |
| EPS Diluted | $0.01 | -$0.17 | -$0.02 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR